Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Griffith University | OTHER |
| Sarawak General Hospital | OTHER |
| University of Malaya | OTHER |
| The University of Queensland |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
An intervention study to determine if a longer duration of antibiotics (compared to shorter duration) improves the short and long term clinical outcomes of children hospitalised for pneumonia
A multi-centre double-blind randomised controlled trial to determine if a longer duration of amoxicillin-clavulanic acid (compared to shorter duration) improves the short and long term clinical outcomes of children hospitalised with community-acquired pneumonia, in Indigenous children and a developing country
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Active arm: Amoxicillin-clavulanic Acid | Experimental | 8 days of oral amoxicillin-clavulanic Acid 400/57 duo formulation (70-90mg/kg/day, twice daily dosing: max 980mg per day) |
|
| Placebo arm | Placebo Comparator | 8 days of oral placebo (equivalent volume as the active arm) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Amoxicillin-clavulanic Acid | Drug |
| ||
| Placebo (for Amoxicillin-clavulanic Acid) |
| Measure | Description | Time Frame |
|---|---|---|
| The proportion without chronic respiratory symptoms and signs or bronchiectasis. | Any further chronic respiratory symptoms and signs or bronchiectasis though the child's medical records (community or hospital) will be captured. These children will be reviewed at 24 months, however many children will reside in geographically isolated locations, thus a range of 23-25 months is a reasonable timeframe to capture clinically important outcomes. | Clinical review at 24 months (range 23-25 months) |
| Measure | Description | Time Frame |
|---|---|---|
| The proportion with clinical cure (i.e. complete resolution of respiratory symptoms and signs). | Children will have a standardised respiratory clinical assessment, completed by either a member of the study team or health provider. These children will be reviewed at week 4, however many children will reside in geographically isolated locations, thus a range of 4-6 weeks is a reasonable time frame to capture clinically important outcomes. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Anne Chang, PhD | Menzies School of Health Research | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Menzies School of Health Research | Darwin | Northern Territory | 0812 | Australia | ||
| University Malaya Medical Centre and Klang Hospital |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011014 | Pneumonia |
| ID | Term |
|---|---|
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D019980 | Amoxicillin-Potassium Clavulanate Combination |
| ID | Term |
|---|---|
| D019818 | Clavulanic Acid |
| D002969 | Clavulanic Acids |
| D047090 | beta-Lactams |
| D007769 | Lactams |
Not provided
Not provided
| OTHER |
| Queensland University of Technology | OTHER |
| Nanyang Technological University | OTHER |
Not provided
Not provided
Not provided
Not provided
| Drug |
|
| Clinical review week 4 (range 4-6 weeks) |
| Time to next respiratory-related hospitalisation assessed by chart reviews | Data will be captured through chart reviews of children's medical records (e.g. hospital and/or community health record) and/or information from parents in next 12 months | Clinical review week 4 (range 4-6 weeks) |
| Adverse events | Adverse effects will be monitored (anorexia, nausea, vomiting, abdominal pain, diarrhoea, rashes) while children are actively taking trial medication (e.g. 8 days). Parents will also keep a diary of adverse events. | Adverse events monitored while participant taking trial medication |
| Nasopharyngeal bacteria antibiotic resistance patterns | Nasopharyngeal respiratory antibiotic resistance will be assessed using nasal swabs. Nasopharyngeal respiratory bacterial pathogens and antibiotic resistance will be assessed using research laboratory's previously published methods. | Baseline (admission to hospital, week 4 (range 4-6 weeks) and 12 months (range 12-14 months) |
| Gene expression data | Gene expression micro-arrays will be performed in a subgroup of children (where bloods can be obtained) | Baseline (hospital admission) and 4-6 weeks (where possible) |
| Kuala Lumpur |
| Kuala Lumpur |
| 59100 |
| Malaysia |
| Sabah Women and Children's Hospital | Kota Kinabalu | Sabah | 88996 | Malaysia |
| Sarawak General Hospital | Sibu | Sarawak | 96000 | Malaysia |
| Starship Children's Hospital & KidzFirst Hospital | Auckland | Auckland | 1142 | New Zealand |
| D000577 |
| Amides |
| D009930 | Organic Chemicals |
| D000658 | Amoxicillin |
| D000667 | Ampicillin |
| D010400 | Penicillin G |
| D010406 | Penicillins |
| D013457 | Sulfur Compounds |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D004338 | Drug Combinations |
| D004364 | Pharmaceutical Preparations |